GB2459657A - Postnatal dietary supplement. - Google Patents
Postnatal dietary supplement. Download PDFInfo
- Publication number
- GB2459657A GB2459657A GB0807735A GB0807735A GB2459657A GB 2459657 A GB2459657 A GB 2459657A GB 0807735 A GB0807735 A GB 0807735A GB 0807735 A GB0807735 A GB 0807735A GB 2459657 A GB2459657 A GB 2459657A
- Authority
- GB
- United Kingdom
- Prior art keywords
- vitamin
- acid
- dha
- pharmaceutical composition
- lactation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000015872 dietary supplement Nutrition 0.000 title 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 196
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 98
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 98
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 89
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 74
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 74
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 74
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 74
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 63
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 52
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 52
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 51
- 229960002477 riboflavin Drugs 0.000 claims abstract description 51
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 50
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 50
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 50
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 48
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 43
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000011575 calcium Substances 0.000 claims abstract description 37
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 37
- 230000006651 lactation Effects 0.000 claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 34
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 32
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 32
- 239000011712 vitamin K Substances 0.000 claims abstract description 32
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 32
- 229940046010 vitamin k Drugs 0.000 claims abstract description 32
- 230000036541 health Effects 0.000 claims abstract description 31
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 28
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 27
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 27
- 229960003495 thiamine Drugs 0.000 claims abstract description 27
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 26
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 26
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 26
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 26
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 26
- 239000011648 beta-carotene Substances 0.000 claims abstract description 26
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 26
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 26
- 229960002747 betacarotene Drugs 0.000 claims abstract description 26
- 239000010949 copper Substances 0.000 claims abstract description 26
- 229910052802 copper Inorganic materials 0.000 claims abstract description 26
- 239000011777 magnesium Substances 0.000 claims abstract description 26
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 26
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 26
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 26
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 26
- 235000019192 riboflavin Nutrition 0.000 claims abstract description 26
- 239000002151 riboflavin Substances 0.000 claims abstract description 26
- 239000011669 selenium Substances 0.000 claims abstract description 26
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 26
- 235000019157 thiamine Nutrition 0.000 claims abstract description 26
- 239000011721 thiamine Substances 0.000 claims abstract description 26
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 26
- 239000011718 vitamin C Substances 0.000 claims abstract description 26
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 26
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 25
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 25
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229910052742 iron Inorganic materials 0.000 claims abstract description 25
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 25
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 25
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 25
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 25
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 25
- 239000011709 vitamin E Substances 0.000 claims abstract description 25
- 229940046009 vitamin E Drugs 0.000 claims abstract description 25
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 25
- 239000011701 zinc Substances 0.000 claims abstract description 25
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 25
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229960000304 folic acid Drugs 0.000 claims abstract description 24
- 235000019152 folic acid Nutrition 0.000 claims abstract description 24
- 239000011724 folic acid Substances 0.000 claims abstract description 24
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960002685 biotin Drugs 0.000 claims abstract description 21
- 235000020958 biotin Nutrition 0.000 claims abstract description 21
- 239000011616 biotin Substances 0.000 claims abstract description 21
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 16
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 16
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 16
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 13
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 13
- 235000021323 fish oil Nutrition 0.000 claims abstract description 12
- 229940088594 vitamin Drugs 0.000 claims abstract description 12
- 229930003231 vitamin Natural products 0.000 claims abstract description 12
- 235000013343 vitamin Nutrition 0.000 claims abstract description 12
- 239000011782 vitamin Substances 0.000 claims abstract description 12
- 229930003316 Vitamin D Natural products 0.000 claims abstract 16
- 235000019166 vitamin D Nutrition 0.000 claims abstract 16
- 239000011710 vitamin D Substances 0.000 claims abstract 16
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract 16
- 229940046008 vitamin d Drugs 0.000 claims abstract 16
- 235000005282 vitamin D3 Nutrition 0.000 claims description 18
- 239000011647 vitamin D3 Substances 0.000 claims description 18
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 18
- 229940021056 vitamin d3 Drugs 0.000 claims description 18
- 239000000470 constituent Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 12
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 10
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 9
- 229940045999 vitamin b 12 Drugs 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 239000006014 omega-3 oil Substances 0.000 claims 11
- 239000002253 acid Substances 0.000 claims 4
- 229960003284 iron Drugs 0.000 claims 4
- 235000021388 linseed oil Nutrition 0.000 claims 4
- 239000000944 linseed oil Substances 0.000 claims 4
- 229940091250 magnesium supplement Drugs 0.000 claims 4
- 229940108928 copper Drugs 0.000 claims 3
- 229940091258 selenium supplement Drugs 0.000 claims 3
- 239000000969 carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- -1 Biotm Chemical compound 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 241000282320 Panthera leo Species 0.000 claims 1
- 229930003537 Vitamin B3 Natural products 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 235000018343 nutrient deficiency Nutrition 0.000 claims 1
- 235000019160 vitamin B3 Nutrition 0.000 claims 1
- 239000011708 vitamin B3 Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 2
- 239000011707 mineral Substances 0.000 abstract description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 abstract 2
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 9
- 235000020256 human milk Nutrition 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 210000004251 human milk Anatomy 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000037213 diet Effects 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004373 eye development Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004641 brain development Effects 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000014461 bone development Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008133 cognitive development Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000007472 neurodevelopment Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 230000008132 psychomotor development Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000023715 cellular developmental process Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009554 growth spurt Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 235000021416 maternal diet Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000021032 oily fish Nutrition 0.000 description 1
- 229940127216 oral anticoagulant drug Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, consists of betacarotene, vitamin D, vitamin E, vitamin C, vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B6, folic acid, vitamin B12, pantothenic acid, biotin, vitamin K, iron, magnesium, zinc, iodine, copper, selenium, calcium, omega-3 fish oil which includes DHA (docosahexaenoic Acid) and EPA (eicosapentaenoic Acid). Preferably the vitamins and minerals are provided in a tablet, and the fish oil is administered as a separate capsule.
Description
DESCRIPTION OF INVENTION
Title: Composition for postnatal health and lactation
TECHNICAL FIELD
This invention concerns a composition of biochemical constituents for use in the maintenance of postnatal health, and lactation.
BACKGROUND ART
Since 1990 in the U.K., there has been a steady increase in breast-feeding as women better understand the benefits for the baby in providing essential nutrients and antibodies that can impact their child's long term health. The specific requirements of thousands of women during breast-feeding has never been adequately addressed by the nutritional market, despite the clear scientific rationale, as many Dietary Reference Values (DRY' s) are officially increased for lactation.
The results of the infant feeding study (performed every 5 years by the U.K. Office for National Statistics) in 2005 showed that breastfeeding rates were 76% in the UK compared with 69% in 2000. This significant increase may be explained by the changing demographic age and educational profile of mothers.
The highest incidences of breast-feeding were found among mothers with high education levels, who were over 30 years old and first time mothers.
Milk production during breastfeeding places a large additional physical demand on a mother's body. Additional protein, fatty acids, vitamins and minerals must be supplied from the reserves and the diet. The quality of a mother's breast milk is, to a large extent, dependent on her nutritional intake. A high intake of DHA leads to DFIA rich milk, which is essential for the infant's neuronal development. When babies are fed on DHA rich breast milk it can help support their cognitive development, hand-eye co-ordination, psychomotor development and visual acuity.
During pregnancy, the growing foetus and placenta can increase certain maternal nutritional requirements. As it can be difficult to maintain this requirement through diet alone, supplementation is often recommended by midwives and health professionals to safeguard a mother's diet and replenish natural bodily stores, which are most depleted by the end of pregnancy, and following labour when there is additional blood loss.
This formulation has therefore been devised in order to provide specific follow on support during the postnatal period. It is also formulated to account for the need for a general postnatal supplement for 3-9 months following childbirth, to replace depleted nutrients and assist the body following pregnancy, even if the mother is not breast-feeding.
DISCLOSURE OF INVENTION
The invention concerns a pharmaceutical composition for postnatal health and lactation, that provides nutrients at meaningful and effective levels to safeguard a mothers diet during this period.
The following is the optimal formulation -Daily dosages of the following constituents, provided in 2 tablets per day: Betacarotene -2 mg Vitamin D3 -10 mcg Vitamin B -20 mg Vitamin C -70 mg Vitamin B 1 (Thiamine) -5 mg Vitamin B2 (Riboflavin) -2 mg Vitamin B3 (Niacin) -20 mg VitaminB6-10mg Folic Acid -400 meg Vitamin B 12 -6 mcg Pantothenic acid -6 mg Biotin-lSOmcg Vitamin K -70 meg Iron-16mg Magnesium -150 mg Zinc-15mg Iodine -140 meg Copper -1 mg Selenium -30 meg Calcium-700mg Plus, daily dosages of the following, provided in 1 capsule per day: Omega-3 Fish Oil -600 mg (which includes 3 00mg DFIA (Docosahexaenoic Acid) and 60mg EPA (Eicosapentaenoic Acid RDA / Active Levels: The following are the recommended dietary allowances for some of the constituents, and the reasons for the level chosen: Betacarotene -No RDA established but level within EU safe limits Vitamin D3 -200% -Preferred D3 form for healthy bone development. The official level that is recommended by the N.H.S. National Institute for Health and Clinical Excellence (NICE) for women whilst breast-feeding.
Vitamin E -200% -Higher the RDA level for increased antioxidant protection Vitamin C -117% -Higher the RDA level for increased antioxidant protection Vitamin B 1 (Thiamine) -214% -Water soluble vitamin any excess not required is excreted safely by the body Vitamin B2 (Riboflavin) -125% -Water soluble vitamin any excess not required is excreted safely by the body Vitamin B3 (Niacin) -111% -Water soluble vitamin any excess not required is excreted safely by the body Vitamin B6 -500% -Water soluble vitamin any excess not required is excreted safely by the body Folic Acid -200% -Water soluble vitamin any excess not required is excreted safely by the body Vitamin B 12 -600% -Water soluble vitamin any excess not required is excreted safely by the body Vitamin K -No RDA established but level within EU safe limits Iron -121% -Level needed to prevent anaemia in both mother and developing child.
Magnesium -50% -Level to help maintain healthy levels alongside dietary intake Zinc -100% -At full RDA level as fundamental to many bodily processes and cell division Iodine -93% -Levels help maintain healthy thyroid function Copper -Important trace element whose significance is often overlooked. Well within safe level for daily supplementation Selenium -No RDA established but level within EU safe limits Pantothenic acid -100% -At full RDA to help maintain healthy adrenal function Biotin -100% -At full RDA to help maintain healthy cell division Calcium -100% -The full RNI, to maintain healthy bones and growth Omega 3 Fish Oil -Oral intake levels are in line with research on brain and eye development Relevance of constituents Constituents are included for the following reasons: Betacarotene is converted to Vitamin A as required by the body. It is important for cellular development and immune system function Vitamin D3 is necessary for the absorption and utiisation of calcium.
Vitamin E is an important antioxidant transferred via breastmilk.
Vitamin C is all important for the formation of immune system cells and can help prevent free radical damage.
Vitamin 131 (Thiamine) is needed for a wide range of functions including carbohydrate metabolism and energy production and can improve glucose tolerance.
Vitamin B2 (Riboflavin) is involved in protein and energy metabolism.
Vitamin B3 (Niacin) is essential for carbohydrate metabolism and the circulatory system.
Vitamin B6 is needed for the production of red blood cells and antibodies Folic acid is required for a healthy nervous system and for blood formation. It functions in multiple coenzyme forms in acceptance, redox processing and transfer of one carbon units, including nucleotides and certain amino acids.
Vitamin B12 Maintains a healthy nervous system and contributes to energy release from food.
Pantothenic acid, also known as Vitamin B5, it is involved in cellular growth and metabolism.
Biotin is essential for protein and carbohydrate metabolism.
Vitamin K via breastmilk is especially important for babies to strengthen blood vessels and prevent excessive bleeding. Lack of Vitamin K can cause baemorrhaging and newborn infants are at high risk of Vitamin K deficiency.
Iron is vital for blood formation, and to help prevent anaemia in both mother and developing child.
Magnesium is required for strong bones in mother and child and is involved in many metabolic processes.
Zinc plays a role in hundreds of metabolic processes and is essential for processes such as nucleic acid synthesis, and essential for normal growth.
Iodine plays an important role in growth, development and the regulation of metabolism.
Copper is necessary for a range of processes, including protein and phospholipid synthesis.
Selenium is an important co-factor in antioxidant enzymes which help protect from free radical damage.
Calcium is vital for strong bones. The body has extra requirement when lactating in order to support nutritious breastmilk. Receiving a good supply of calcium in the diet is vital for strong bones and teeth, in addition to the health of the heart, muscles and nerves. Calcium plays an important role in tissue repair and the control of blood pressure and acidity. It is important for growing children, during pregnancy and breast feeding. Researchers found that lactating mothers who do not have enough calcium in their diet, put the bone structures around their teeth at risk. A high calcium diet when breastfeeding ensures healthy foetal bone development with minimised risk of bone loss in the mothers jaw.
Omega 3 Fish Oil Provides rich source of fatty acids DHA (Docosahexaenoic Acid) and EPA (Eicosapentaenoic Acid). Infants only have limited capability to synthesise these essential fatty acids, therefore most requirements must be obtained directly from the mother's milk.
DI-JA (Docosahexaenoic Acid) is the most important fatty acid required for healthy brain and eye development of the foetus. During breastfeeding the infants brain continues to take up DHA and 15% of brain growth occurs after birth. EPA (Eicosapentaenoic Acid) is required for optimum brain function and signalling and learning ability in later life.
DHA and EPA are especially vital during pregnancy and breast-feeding as they form the building blocks of the babys' eyes and brain. DHA is the most important fatty acid required for healthy brain and eye development of the foetus. Each capsule contains 60 mg EPA, which helps to maintain optimum brain function and cell signalling. Adults can obtain DHA and EPA through the conversion of the essential fatty acid alphalinoleic acid (ALA), from vegetable oils such as linseed but the conversion to DHA in particular is not vety efficient.
A more reliable and direct source is the consumption of either oily fish or fish oils with provide a good source of both DHA and EPA. The foetus is reliant on the mother for its DHA and EPA supply through placental transfer whilst in the womb or later via the mothers milk during breastfeeding. The DHA content of human milk is at least 30 times that of other mammals. After delivery, maternal DHA reserves are replaced slowly over a period of 5-6 months. In order to limit depletion of the mothers own reserves it is important that she consumes additional amounts of these fatty acids during both pregnancy and breastfee ding.
DHA is the predominant fatty acid in the central nervous system, found in the structural walls of brain cells. The foetal brain is made up of 60% fats of which 40% is DHA. There is a large increase in DHA uptake by the foetus and a corresponding increase in cerebal DHA content during the last trimester of pregnancy and the first post natal months. At birth, the baby's brain weight is about 70% of an adult's brain weight; 15% of brain growth occurs during infancy and the pre-school years. DHA is important throughout this period of development. DHA is found in even greater concentrations in the retina, where it contributes up to 60% of the fatty acid content. Research has shown that when the growing baby receives DHA from the third trimester onwards and during breastfeeding, circulating levels of DHA are higher, which can help to maintain healthy eye development and visual acuity (clarity of vision). The other Omega-3 fatty acid provided in the composition is EPA, which is required for optimal brain function and cell signaling (the process of communication between nerve cells) and becomes increasingly significant for children after birth in respect to areas such as learning ability and concentration. There are a growing number of studies that have positively correlated fatty acid supplementation of the maternal diet, with higher mental processing scores in the infant at four years old. DHA is important for development of the central nervous system and there is a growth spurt during the last trimester of pregnancy and the first postnatal months. At this time there is a large increase in uptake and cerebral DHA content and the foetus and newborn infant depend entirely on maternal supply of DHA. A high intake of DHA leads to DHA rich milk, which is essential for the infant neuronal development. When babies are fed DHA rich breast milk it can help support their cognitive development, hand-eye co-ordination, psychomotor development and visual acuity.
Suggested Daily Intake/Dosage: 2 tablets and 1 capsule per day with a main meal, with a full glass of water or cold drink.
Recommended Contra -Indications/Warnings: The formulation should be taken on a full stomach, with plenty of water.
Recommended to ensure maximum absorption of nutrients and to facilitate swallowing of tablet.
As the formulation contains vitamin K, if somebody is taking oral anticoagulants (e.g. warfarin) these tablets should not be taken except on the advice of a doctor. Vitamin K is not known to specifically interact with the action of aspirin or heparin.
Keep out of reach of children, because the tablets contains Iron which if taken in excess may be harmful to young children.
INDUSTRIAL APPLICABILITY
According to this invention, there is a pharmaceutical composition, or the use of that composition in the manufacture of a medicament, for combined, sequential or simultaneous administration, in any form, via any biological route, for use in the maintenance of postnatal health, and lactation. In its optimal embodiment the composition consists of a daily intake of 2 tablets that consist of: 2mg Betacarotene, lomcg Vitamin D3, 20mg Vitamin E, 70mg Vitamin C, 5mg Vitamin B 1 (Thiamine), 2mg Vitamin B2 (Riboflavin), 20mg Vitamin B3 (Niacin), 10mg Vitamin B6, 400mcg Folic Acid, 6mcg Vitamin B12, 6mg Pantothenic acid, lSOmcg Biotin, 70mcg Vitamin K, 16mg Iron, 150mg Magnesium, 15mg Zinc, l4Omcg Iodine, 1mg Copper, 3omcg Selenium, 700mg Calcium; plus 1 capsule that consists of: 600mg Omega-3 Fish Oil which includes 3 00mg DHA (Docosahexaenoic Acid) and 60mg EPA (Eicosapentaenoic Acid).
Claims (18)
- CLAIMS1. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of average daily dosages of approximately 2mg Betacarotene, l0mcg Vitamin D3, 20mg Vitamin E, 70mg Vitamin C, 3mg Vitamin Bi (Thiamine), 2mg Vitamin B2 (Riboflavin), 20mg Vitamin B3 (Niacin), 10mg Vitamin B6, 400mcg Folic Acid, 6mcg Vitamin B12, 6mg Pantothenic acid, l5Omcg Biotin, 7omcg Vitamin K, 17mg Iron, 150mg Magnesium, 15mg Zinc, l4Omcg Iodine, 1mg Copper, 30mcg Selenium, 700mg Calcium, 600mg Omega-3 Fish Oil which includes 3 00mg DHA (Docosahexaenoic Acid) and 60mg EPA (Eicosapentaenoic Acid).
- 2. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of approximately 2mg Betacarotene, lOmcg Vitamin D3, 20mg Vitamin E, 70mg Vitamin C, 5mg Vitamin B 1 (Thiamine), 2mg Vitamin B2 (Riboflavin), 20mg Vitamin B3 (Niacin), 10mg Vitamin B6, 400mcg Folic Acid, 6mcg Vitamin B12, 6mg Pantothenic acid, 1 S0mcg Biotin, 70mcg Vitamin K, 16mg Iron, 150mg Magnesium, 15mg Zinc, l4Omcg Iodine, 1mg Copper, 30mcg Selenium, 700mg Calcium, 600mg Omega-3 Fish Oil which includes 300mg DI-IA (Docosahexaenoic Acid) and 60mg EPA (Eicosapentaenoic Acid).
- 3. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of average daily dosages of: 1mg to 4mg Betacarotene, Smcg to l5mcg Vitamin D3, 10mg to 30mg Vitamin E, 35mg to 100mg Vitamin C, 3mg to 7mg Vitamin BI (Thiamine), 1mg to 3mg Vitamin B2 (Riboflavin), 10mg to 30mg Vitamin B3 (Niacin), 5mg to 15mg Vitamin B6, 200mcg to 600mcg Folic Acid, 3mcg to 9mcg Vitamin B12, 3mg to 9mg Pantothenic acid, 75mcg to 225mcg Biotin, 35mcg to lOOmcg Vitamin K, 8mg to 24mg Iron, 75mg to 225mg Magnesium, 7mg to 22mg Zinc, 7Omcg to 2lOmcg Iodine, 0.5mg to 1.5mg Copper, l5mcg to 45mcg Selenium, 400mg to 1000mg Calcium, 300mg to 900mg Omega-3 Fish Oil which includes 150mg to 450mg DHA (Docosahexaenoic Acid) and 30mg to 90mg EPA (Eicosapentaenoic Acid).
- 4. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of: 1mg to 4mg Betacarotene, 5mcg to l5mcg Vitamin D3, 10mg to 30mg Vitamin E, 35mg to 100mg Vitamin C, 3mg to 5mg Vitamin Bi (Thiamine), 1mg to 3mg Vitamin B2 (Riboflavin), 10mg to 30mg Vitamin B3 (Niacin), 5mg to 15mg Vitamin B6, 200mcg to 600mcg Folic Acid, 3mcg to 9mcg Vitamin B12, 3mg to 9mg Pantothenic acid, 75mcg to 225mcg Biotm, 35mcg to lOOmcg Vitamin K, 8mg to 24mg lion, 75mg to 225mg Magnesium, 7mg to 22mg Zinc, 7Omcg to 2lOmcg Iodine, 0.5mg to 1.5mg Copper, l5mcg to 45mcg Selenium, 400mg to 1000mg Calcium, 300mg to 900mg Omega-3 Fish Oil which includes 150mg to 450mg DHA (Docosahexaenoic Acid) and 30mg to 90mg EPA (Eicosapentaenoic Acid).
- 5. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of Betacarotene, Vitamin D3, Vitamin E, Vitamin C, Vitamin B 1 (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B12, Pantothenic acid, Biotin, Vitamin K, Iron, Magnesium, Zinc, Iodine, Copper, Selenium, Calcium, Omega-3 fatty acids 6. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising Betacarotene, Vitamin D3, Vitamin E, Vitamin C, Vitamin B 1 (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B12, Pantothenic acid, Biotin, Vitamin K, Iron, Magnesium, Zinc, Iodine, Copper, Selenium, Calcium, Omega-3 fatty acids.7. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 150mg to 450mg DHA (Docosahexaenoic Acid), Smcg to l5mcg Vitamin D, 40mcg to lOOmcg Vitamin K, 400mg to 1000mg Calcium, in excess of 50mg EPA (Eicosapentaenoic Acid), and one or more of Betacarotene, Vitamin E, Vitamin C, Vitamin B 1 (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B12, Pantothenic acid, Biotin, Iron, Magnesium, Zinc, Iodine, Copper, Selenium.8. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising DHA (Docosahexaenoic Acid), Vitamin D, Vitamin K, more than 400mg Calcium, in excess of 50mg EPA (Eicosapentaenoic Acid), and one or more of Betacarotene, Vitamin E, Vitamin C, Vitamin Bi (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B12, Pantothenic acid, Biotin, Iron, Magnesium, Zinc, Iodine, Copper, Selenium.9. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising DHA (Docosahexaenoic Acid), Vitamin D, Vitamin K, more than 400mg Calcium, EPA (Eicosapentaenoic Acid), and one or more of: Betacarotene, Vitamin E, Vitamin C, Vitamin Bi (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folk Acid, Vitamin B 12, Pantothenic acid, Biotin, Iron, Magnesium, Zinc, Iodine, Copper, Selenium.10. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 150mg to 450mg DHA (Docosahexaenoic Acid), Smcg to l5mcg Vitamin D, 40mcg to lOOmcg Vitamin K, 400mg to 1000mg Calcium, and one or more of: Betacarotene, Vitamin E, Vitamin C, Vitamin B 1 (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B12, Pantothenic acid, Biotin, Iron, Magnesium, Zinc, Iodine, Copper, Selenium, Omega-3 fatty acids.11. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising DHA (Docosahexaenoic Acid), Vitamin D, Vitamin K, and more than 400mg Calcium, and one or more of: Betacarotene, Vitamin E, Vitamin C, Vitamin B 1 (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B 12, Pantothenic acid, Biotm, Iron, Magnesium, Zinc, Iodine, Copper, Selenium, Omega-3 fatty acids.12. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 150mg to 450mg DHA (Docosahexaenoic Acid), Smcg to 1 Smcg Vitamin D, and 400mg to 1000mg Calcium and one or more of: Betacarotene, Vitamin E, Vitamin C, Vitamin B 1 (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B 12, Pantothenic acid, Biotin, Iron, Magnesium, Zinc, Iodine, Copper, Selenium, Omega-3 fatty acids.13. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising DFIA (Docosahexaenoic Acid), Vitamin D, and more than 400mg Calcium and one or more of: Betacarotene, Vitamin E, Vitamin C, Vitamin B 1 (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B 12, Pantothenic acid, Biotin, Iron, Magnesium, Zinc, Iodine, Copper, Selenium, Omega-3 fatty acids.14. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 150mg to 450mg DHA (Docosahexaenoic Acid), Smcg to l5mcg Vitamin D, 4Omcg to lOOmcg Vitamin K, 400mg to 1000mg Calcium, and in excess of 50mg EPA (Eicosapentaenoic Acid).15. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising DHA (Docosahexaenoic Acid), Vitamin D, Vitamin K, more than 400mg Calcium, and in excess of 50mg EPA (Eicosapentaenoic Acid).16. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising DI-LA (Docosahexaenoic Acid), Vitamin D, Vitamin K, more than 400mg Calciutn, and EPA (Eicosapentaenoic Acid).17. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 150mg to 450mg DHA (Docosahexaenoic Acid), 5mcg to l5mcg Vitamin D, 4Omcg to lOOmcg Vitamin K, and 400mg to 1000mg Calcium.18. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising DHA (Docosahexaenoic Acid), Vitamin D, Vitamin K, and more than 400mg Calcium.19. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising average daily dosages of 150mg to 450mg DHA (Docosahexaenoic Acid), Smcg to l5mcg Vitamin D, and 400mg to 1000mg Calcium.20. A pharmaceutical composition for postnatal health and lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising DHA (Docosahexaenoic Acid), Vitamin D, and more than 400mg Calcium.21. A claim according to any one of the previous claims in which the pharmaceutical composition does not comprise more than 3 00mg of amino acids in a protein or amino acid complex form.22. A claim according to any one of the preceding claims in which Vitamin D is used instead of Vitamin D3.23. A claim according to any one of the preceding claims in which DHA (Docosahexaenpoic acid) and EPA (Eicosapentaenoic acid) are used instead of Omega-3 fatty acids.24. A claim according to any one of the preceding claims in which flax seed oil or linseed oil is used instead of Omega-3 fatty acids.25. A pharmaceutical composition according to any one of the preceding claims for any use in postnatal health and lactation.26. A pharmaceutical composition according to any one of the preceding claims for any use other than postnatal health and lactation.27. A claim according to any one of the preceding claims in which the pharmaceutical composition includes one or more carriers or excipients.28. The use in the manufacture of a meclicament using a composition as described in Claims 1 to 27.29. A method of treatment of postnatal nutritional deficiencies and insufficient breat milk production, using a pharmaceutical composition as described in Claims 1to27.Amendments to the claims have been filed as followsCLAIMS1. A pharmaceutical composition that is specifically for lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of average daily dosages of (a) more than 400mg Calcium, (b) more than 250mg DHA (Docosahexaenoic Acid) and (c) Betacarotene, Vitamin D3, Vitamin E, Vitamin C, Vitamin Bi (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B 12, Pantothenic acid, Biotin, Vitamin K, Iron, Magnesium, Zinc, Iodine, Copper, Selenium, EPA (Eicosapentaenoic Acid); in which the DHA (Docosahexaenoic Acid) and EPA (Eicosapentaenoic Acid) are in a tablet or capsule that is administered separately from the other constituents.2. A pharmaceutical composition that is specifically for lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising of average daily dosages of(a) more than 400mg Calcium, (b) more than 250mg DHA (Docosahexaenoic Acid) and (c) Betacarotene, Vitamin D3, S...Vitamin E, Vitamin C, Vitamin Bi (Thiamine), Vitamin B2 (Riboflavin), S...Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B 12, Pantothenic acid, * Biotin, Vitamin K, Iron, Magnesium, Zinc, Iodine, Copper, Selenium, EPA *** (Eicosapentaenoic Acid); in which the DHA (Docosahexaenoic Acid) and EPA * : (Eicosapentaenoic Acid) are in a tablet or capsule that is administered separately from the other constituents.3. A pharmaceutical composition that is specifically for lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of average daily dosages of (a) more than 400mg Calcium, (b) more than 250mg DHA (Docosahexaenoic Acid) and (c) approximately 2mg Betacarotene, lOmcg Vitamin D3, 20mg Vitamin E, 70mg Vitamin C, 5mg Vitamin Bi (Thiamine), 2mg Vitamin B2 (Riboflavin), 20mg Vitamin B3 (Niacin), 10mg Vitamin B6, 400mcg Folic Acid, 6mcg Vitamin 1312, 6mg Pantothenic acid, lSOmcg Biotin, 7Omcg Vitamin K, 16mg Iron, 150mg Magnesium, 15mg Zinc, l4Omcg Iodine, 1mg Copper, 3Omcg Selenium, 60mg EPA (Eicosapentaenoic Acid); in which the DHA (Docosahexaenoic Acid) and EPA (Eicosapentaenoic Acid) are in a tablet or capsule that is administered separately from the other constituents.4. A pharmaceutical composition that is specifically for lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comrpising of average daily dosages of (a) more than 400mg Calcium, (b) more than 250mg DHA (Docosahexaenoic Acid), and (c) approximately 2mg Betacarotene, lOnicg Vitamin D3, 20mg Vitamin E, 70mg Vitamin C, 5mg Vitamin B 1 (Thiamine), 2mg Vitamin B2 (Riboflavin), 20mg Vitamin B3 *:: (Niacin), 10mg Vitamin B6, 400mcg Folic Acid, 6mcg Vitamin B12, 6mg *. Pantothenic acid, lSOmcg Biotin, 7Omcg Vitamin K, 16mg Iron, 150mg *: Magnesium, 15mg Zinc, l4Omcg Iodine, 1mg Copper, 30mcg Selenium, 60mg *0** *:. EPA (Eicosapentaenoic Acid); in which the DHA (Docosahexaenoic Acid) and EPA (Eicosapentaenoic Acid) are in a tablet or capsule that is administered : : separately from the other constituents. a *5. A pharmaceutical composition that is specifically for lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of average daily dosages of (a) more than 400mg Calcium, (b) more than 250mg DHA (Docosahexaenoic Acid) and (c) approximately 1mg to 4mg Betacarotene, 5mcg to l5mcg Vitamin D3, 10mg to 30mg Vitamin E, 35mg to 100mg Vitamin C, 3mg to 7mg Vitamin Bi (Thiamine), 1mg to 3mg Vitamin B2 (Riboflavin), 10mg to 30mg Vitamin B3 (Niacin), 5mg to 15mg Vitamin B6, 200mcg to 600mcg Folic Acid, 3mcg to 9mcg Vitamin B12, 3mg to 9mg Pantothenic acid, 75mcg to 225mcg Biotin, 35mcg to lOOmcg Vitamin K, 8mg to 24mg Iron, 75mg to 225mg Magnesium, 7mg to 22mg Zinc, 7omcg to 2lOmcg Iodine, 0.5mg to 1.5mg Copper, lsmcg to 45mcg Selenium, and 30mg to 90mg EPA (Eicosapentaenoic Acid); in which the DHA (Docosahexaenoic Acid) and EPA (Eicosapentaenoic Acid) are in a tablet or capsule that is administered separately from the other constituents.
- 6. A pharmaceutical composition that is specifically for lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, comprising of average daily dosages of (a) more than 400mg Calcium, (b) more than 25 0mg DHA (Docosahexaenoic Acid), and (c) approximately 1mg to 4mg Betacarotene, 5mcg to l5mcg Vitamin D3, 10mg to 30mg Vitamin E, 35mg to :::: 100mg Vitamin C, 3mg to 7mg Vitamin Bi (Thiamine), 1mg to 3mg Vitamin *::* 82 (Riboflavin), 10mg to 30mg Vitamin B3 (Niacin), 5mg to 15mg Vitamin B6, 200mcg to 600mcg Folic Acid, 3mcg to 9mcg Vitamin B12, 3mg to 9mg :. Pantothenic acid, 75mcg to 225mcg Biotin, 35mcg to lOOmcg Vitamin K, 8mg to 24mg Iron, 75mg to 225mg Magnesium, 7mg to 22mg Zinc, 70mcg to : : 2lOmcg Iodine, 0.5mg to 1.5mg Copper, l5mcg to 45mcg Selenium, and 30mg * to 90mg EPA (Eicosapentaenoic Acid); in which the DFIA (Docosahexaenoic Acid) and EPA (Eicosapentaenoic Acid) are in a tablet or capsule that is administered separately from the other constituents.
- 7. A pharmaceutical composition that is specifically for lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of average daily dosages of (a) more than 400mg Calciwn, (b) more than 25 0mg D}-IA (Docosahexaenoic Acid) and (c) ten or more of: Betacarotene, Vitamin D3, Vitamin E, Vitamin C, Vitamin Bi (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic Acid, Vitamin B 12, Pantothenic acid, Biotm,, Vitamin K, Iron, Magnesium, Zinc, Iodine, Copper, Selenium, EPA (Eicosapentaenoic Acid); in which the DFIA (Docosahexaenoic Acid) and EPA (Eicosapentaenoic Acid) are in a tablet or capsule that is administered separately from the other constituents.
- 8. A pharmaceutical composition that is specifically for lactation, for combined, sequential or simultaneous administration, in any form, via any biological route, consisting essentially of average daily dosages of (a) more than 400mg Calcium, (b) more than 25 0mg DHA (Docosahexaenoic Acid) and (c) five or more of Betacarotene, Vitamin D3, Vitamin E, Vitamin C, Vitamin Bi (Thiamine), Vitamin B2 (Riboflavin), Vitamin B3 (Niacin), Vitamin B6, Folic *:::: Acid, Vitamin B12, Pantothenic acid, Biotin, Vitamin K, Iron, Magnesium, * :* Zinc, Jo dine, Copper, Selenium, EPA (Eicosapentaenoic Acid); in which the : DFIA (Docosahexaenoic Acid) and EPA (Eicosapentaenoic Acid) are in a tablet I...:. or capsule that is administered separately from the other constituents.S:
- 9. A claim according to any one of the preceding claims in which Omega-3 fatty acids generally are used instead of DHA (Docosahexaenpoic acid) and EPA (Eicosapentaenoic acid).
- 10. A claim according to claim 9 in which the Omega-3 fatty acids come from Omega-3 Fish Oil.
- 11. A claim according to claim 10 in which the quantity of Omega-3 Fish Oil used is 600 mg (which includes 3 00mg DHA (Docosahexaenoic Acid) and 60mg EPA (Eicosapentaenoic Acid).
- 12. A claim according to any one of the preceding claims in which the quantity of Calcium is 400mg to 1000mg.
- 13. A claim according to any one of the preceding claims in which the quantity of Calcium is 700mg.
- 14. A claim according to any one of claims I to 13 in which the pharmaceutical composition does not comprise more than 3 00mg of amino acids in a protein or amino acid complex form.
- 15. A claim according to any one of claims 1 to 13 in which flax seed oil or : linseed oil is used instead of Omega-3 fatty acids. * ,u* * I **...
- 16. A claim according to any one of claims 1 to 13 for use in postnatal health :. and lactation. I,: :
- 17. A claim according to any one of claims 1 to 13 in which the pharmaceutical * composition includes one or more carriers or excipients.
- 18. The use in the manufacture of a medicament of a composition as described inClaims ito 17.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0807735A GB2459657A (en) | 2008-04-29 | 2008-04-29 | Postnatal dietary supplement. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0807735A GB2459657A (en) | 2008-04-29 | 2008-04-29 | Postnatal dietary supplement. |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0807735D0 GB0807735D0 (en) | 2008-06-04 |
GB2459657A true GB2459657A (en) | 2009-11-04 |
Family
ID=39522707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0807735A Withdrawn GB2459657A (en) | 2008-04-29 | 2008-04-29 | Postnatal dietary supplement. |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2459657A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160038553A1 (en) * | 2014-08-06 | 2016-02-11 | Fairhaven Health, Llc | Nutritional supplement comprising herbal galactagogue |
WO2016027252A1 (en) * | 2014-08-20 | 2016-02-25 | Nestec S.A. | Preconception/prenatal/postnatal optimal nutrition system, compositions and kits for use therein, and methods of making and using same |
IT202000024736A1 (en) * | 2020-10-20 | 2022-04-20 | Lsh Soc Benefit A Responsabilita Limitata | IMMUNOSTIMULATING PHARMACEUTICAL COMPOSITION |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112401066B (en) * | 2020-11-18 | 2022-10-28 | 乖宝宠物食品集团股份有限公司 | Pet food beneficial to maintaining bone health |
CN112790278B (en) * | 2021-01-22 | 2022-10-28 | 乖宝宠物食品集团股份有限公司 | A complete pet canned food for maintaining bone health |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020102330A1 (en) * | 2000-12-05 | 2002-08-01 | Pbm Products, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity -maintaining agents |
US20030216351A1 (en) * | 1999-06-01 | 2003-11-20 | Drugtech Corporation | Nutritional supplements |
-
2008
- 2008-04-29 GB GB0807735A patent/GB2459657A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030216351A1 (en) * | 1999-06-01 | 2003-11-20 | Drugtech Corporation | Nutritional supplements |
US20020102330A1 (en) * | 2000-12-05 | 2002-08-01 | Pbm Products, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity -maintaining agents |
Non-Patent Citations (3)
Title |
---|
http://vitabiotics.com/pregnacare/pregnacare_formula.aspx * |
http://www.materna.ca/About/Default.asp * |
http://www.superliving.co.uk/pharmacy/family-health/women-s-health/pregnancy/sanatogen-pronatal-omega-3-30-tablets-30-capsules.html * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160038553A1 (en) * | 2014-08-06 | 2016-02-11 | Fairhaven Health, Llc | Nutritional supplement comprising herbal galactagogue |
WO2016027252A1 (en) * | 2014-08-20 | 2016-02-25 | Nestec S.A. | Preconception/prenatal/postnatal optimal nutrition system, compositions and kits for use therein, and methods of making and using same |
IT202000024736A1 (en) * | 2020-10-20 | 2022-04-20 | Lsh Soc Benefit A Responsabilita Limitata | IMMUNOSTIMULATING PHARMACEUTICAL COMPOSITION |
Also Published As
Publication number | Publication date |
---|---|
GB0807735D0 (en) | 2008-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8007853B2 (en) | Vitamin/mineral composition with DHA | |
US7112609B2 (en) | Nutritional supplements | |
KR101075816B1 (en) | Total enteral nutritious composition | |
US20020044961A1 (en) | Nutritional formulations | |
Mangili et al. | Feeding of preterm infants and fortification of breast milk | |
WO2000072842A1 (en) | Nutritional supplements | |
JP2004521141A (en) | High calorie fluid oral supplement | |
KR20110108399A (en) | Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health | |
GB2459657A (en) | Postnatal dietary supplement. | |
EP2076256B1 (en) | Meal replacement compositions and weight control method | |
CN104171025A (en) | Selenium-rich edible oil suitable for women and children | |
CN101091571A (en) | Nutrition peptide for full day | |
US20130064924A1 (en) | Nutritional supplement for use under physiologically stressful conditions | |
CN102511858A (en) | Thickened red jujube pulp suitable for being taken by pregnant women and manufacturing technology of same | |
CN1094348C (en) | Compound vitamin drop for infant | |
US20130115201A1 (en) | Fluid Supplement with Prenatal Vitamins | |
GB2458467A (en) | Dietary supplement for maintenance of bone health | |
WO2014057296A1 (en) | Nutritional supplement for patients suffering from rheumatic diseases | |
abbas Fadhil | The Effect of Vitamin D Deficiency in Women and its Symptoms and Treatment Methods | |
PL241200B1 (en) | Pharmaceutical composition containing docosahexanoic acid and its application | |
Rani | Food and nutrition concerns in child development | |
Zulaikha et al. | THE CALCIUM SUPPLEMENTATION DURING PREGNANCY AGAINST DISORDERS OF GROWTH AND DEVELOPMENT OF TODDLERS | |
EP3389666A1 (en) | Compositions comprising 3'-o-glucuronide epicatechin and methods of making and using such compositions | |
KR20160002034U (en) | Multi-doses pack of dietary supplements | |
WO2022157745A1 (en) | Multi micro-nutrient (mmn): composition for pregnancy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R108 | Alteration of time limits (patents rules 1995) |
Free format text: EXTENSION APPLICATION Effective date: 20121219 Free format text: EXTENSION ALLOWED Effective date: 20130301 |
|
APTC | Appeals to the court |
Free format text: APPEAL LODGED; APPEAL AGAINST THE DECISION OF THE COMPTROLLER DATED 23 MAY 2013 LODGED WITH THE COURT OF APPEAL ON 11 JULY 2013. |
|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |